The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
In vitro modulation of the glucocorticoid receptor by antidepressants
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressants have been reported to increase GR mRNA expression (Carvalho and Pariante, 2008;Funato et al, 2006;Heiske et al, 2003;Vedder et al, 1999)”
From Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients (2012) · cites this paper as Carvalho and Pariante, 2008
In the citing paper
“GR function as measured using the translocation of the receptor to the nucleus (Carvalho and Pariante, 2008;Funato et al, 2006;Heiske et al, 2003;Pariante et al, 1997)”
From Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients (2012) · cites this paper as Carvalho and Pariante, 2008
In the citing paper
“GR protein expression (Carvalho and Pariante, 2008;Hery et al, 2000;Lai et al, 2003;Pepin et al, 1992)”
From Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients (2012) · cites this paper as Carvalho and Pariante, 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 2×
“The hyperactivity of the HPA axis in major depression is one of the most consistent findings in psychiatry, occurring in up to 80% of the patients when severely depressed (reviewed in Heuser et al. 1994; Nemeroff 1996; Holsboer 2000; McQuade and Young 2000; Pariante and Miller 2001a, 2003).”
BackgroundSelf-citationBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 2×
“…underlined by genetic investigations which found that polymorphisms of the GR gene and of genes encoding for chaperones of the GR possibly contribute to the development of depressive symptoms and play a role in the variability of antidepressant response (Binder et al. 2004; van Rossum et al. 2006).”
BackgroundMcEwen, B. S., Biron, C. A., Brunson, K. W., Bulloch, K., Chambers, W. H., Dhabhar, F. S., Goldfarb, R. H., Kitson, R. P., Miller, A. H., Spencer, R. L., et al. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(96)00012-4 · Cited by 837 · cited 1×
“The GR is therefore considered to be more important in the regulation of the response to stress when endogenous levels of glucocorticoids are high (McEwen et al. 1997; de Kloet et al. 1998).”
BackgroundThe combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
Heuser, I., Yassouridis, A., & Holsboer, F. (1994) · Journal of Psychiatric Research · doi:10.1016/0022-3956(94)90017-5 · Cited by 662
Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
Antoni, F. A. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1004 · Cited by 636
Regulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463 · cited 1×
“Moreover, recent work on the mechanism of action of antidepressants suggests that cAMP and protein kinase A play an important role as mediators of the psychotropic effects of these agents, possibly leading to increased neurogenesis (Rasenick et al. 1996; Duman et al. 2001).”
BackgroundLu, N. Z., & Cidlowski, J. A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.025 · Cited by 455 · cited 1×
“The GR is expressed in almost all tissues in the body, although tissue and cell cycle-specific regulation of GR levels have been reported (Cidlowski et al. 1990; Oakley et al. 1996; Lu and Cidlowski 2005).”
BackgroundZobel, A. W., Nickel, T., Sonntag, A., Uhr, M., Holsboer, F., & Ising, M. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00013-9 · Cited by 354
Research works printed but not linked: 95
- Augustyn M, 2005, Pharmacol Rep, 57, 766
- Axelson DA, 1992, Psychiatr Res, 44, 63, 10.1016/0165-1781(92)90070-J · DOI
- 10.1055/s-2007-979536 · DOI
- Basta-Kaim A, 2006, Neuropsychopharmacology, 31, 853, 10.1038/sj.npp.1300911 · DOI
- Bouron A, 1999, Neuroscience, 90, 729, 10.1016/S0306-4522(98)00480-1 · DOI
- Bouwer C, 2000, Depress Anxiety, 12, 44, 10.1002/1520-6394(2000)12:1<44::AID-DA6>3.0.CO;2-C · DOI
- Budziszewska B, 2000, Br J Pharmacol, 130, 1385, 10.1038/sj.bjp.0703445 · DOI
- Budziszewska B, 2005, Pharmacol Rep, 57, 540
- Burnstein KL, 1994, Mol Endocrinol, 8, 1764
- Cai W, 2005, J Hepatol, 42, 880, 10.1016/j.jhep.2005.01.024 · DOI
- Calfa G, 2003, Psychoneuroendocrinology, 28, 687, 10.1016/S0306-4530(02)00051-3 · DOI
- 10.1001/archpsyc.1981.01780260017001 · DOI · Paper page
- Cidlowski JA, 1990, Mol Endocrinol, 4, 1427, 10.1210/mend-4-10-1427 · DOI
- Cooney JM, 1996, Acta Psychiatr Scand, 94, 449, 10.1111/j.1600-0447.1996.tb09889.x · DOI
- DeBattista C, 2000, Am J Psychiatry, 157, 1334, 10.1176/appi.ajp.157.8.1334 · DOI
- Dinan TG, 1997, Acta Psychiatr Scand, 95, 58, 10.1111/j.1600-0447.1997.tb00374.x · DOI
- Dumser T, 1998, Am J Forensic Med Pathol, 19, 72, 10.1097/00000433-199803000-00014 · DOI
- Eickelberg O, 1999, J Biol Chem, 274, 1005, 10.1074/jbc.274.2.1005 · DOI · Paper page
- Falkenstein E, 2000, Pharmacol Rev, 52, 513, 10.1016/S0031-6997(24)01468-6 · DOI · Paper page
- Gold PW, 1988, N Engl J Med, 319, 348, 10.1056/NEJM198808113190606 · DOI · Paper page
- Gormley GJ, 1985, Am J Psychiatry, 142, 1278, 10.1176/ajp.142.11.1278 · DOI · Paper page
- Herr AS, 2003, Neuroendocrinology, 78, 12, 10.1159/000071701 · DOI
- Hery M, 2000, J Neurochem, 74, 406, 10.1046/j.1471-4159.2000.0740406.x · DOI · Paper page
- Heuser IJ, 1996, Am J Psychiatry, 153, 93, 10.1176/ajp.153.1.93 · DOI · Paper page
- Holsboer F, 2000, Neuropsychopharmacology, 23, 477, 10.1016/S0893-133X(00)00159-7 · DOI · Paper page
- Ising M, 2005, J Psychiatr Res, 39, 21, 10.1016/j.jpsychires.2004.04.009 · DOI
- Juruena MF, 2004, Rev Bras Psiquiatr, 26, 189, 10.1590/S1516-44462004000300009 · DOI · Paper page
- Karst H, 2005, Proc Natl Acad Sci USA, 102, 19204, 10.1073/pnas.0507572102 · DOI · Paper page
- de Kloet ER, 1998, Endocr Rev, 19, 269
- Lai M, 2003, Neuroscience, 118, 975, 10.1016/S0306-4522(03)00038-1 · DOI · Paper page
- Lauer CJ, 1998, J Psychiatr Res, 32, 393, 10.1016/S0022-3956(98)00026-0 · DOI
- Levitan RD, 2002, J Psychiatry Neurosci, 27, 47
- Linkowski P, 1987, J Clin Endocrinol Metab, 65, 141, 10.1210/jcem-65-1-141 · DOI · Paper page
- Lowy MT, 1990, Neuroendocrinology, 51, 190, 10.1159/000125336 · DOI
- Lowy MT, 1984, Am J Psychiatry, 141, 1365, 10.1176/ajp.141.11.1365 · DOI
- Lowy MT, 1988, Biol Psychiatry, 24, 619, 10.1016/0006-3223(88)90136-9 · DOI · Paper page
- Maddock C, 2001, Epidemiol Psichiatr Soc, 10, 153, 10.1017/S1121189X00005285 · DOI
- Maddock C, 2004, J Psychopharmacol, 18, 41, 10.1177/0269881104040230 · DOI
- Mangelsdorf DJ, 1995, Cell, 83, 835, 10.1016/0092-8674(95)90199-X · DOI · Paper page
- Manier DH, 2000, J Affect Disord, 61, 51, 10.1016/S0165-0327(99)00190-1 · DOI
- McQuade R, 2000, Br J Psychiatry, 177, 390, 10.1192/bjp.177.5.390 · DOI
- Merali Z, 2004, J Neurosci, 24, 1478, 10.1523/JNEUROSCI.4734-03.2004 · DOI · Paper page
- Merry S, 1991, Eur J Cancer, 27, 31, 10.1016/0277-5379(91)90054-H · DOI
- Modell S, 1998, Neuropsychopharmacology, 18, 253, 10.1016/S0893-133X(97)00144-9 · DOI · Paper page
- 10.1016/0960-0760(91)90312-S · DOI · Paper page
- Nalepa I, 1991, Neuroscience, 44, 585, 10.1016/0306-4522(91)90079-4 · DOI
- Nemeroff CB, 1996, Mol Psychiatry, 1, 336
- Oakley RH, 1996, J Biol Chem, 271, 9550, 10.1074/jbc.271.16.9550 · DOI · Paper page
- Okugawa G, 1999, J Neuroendocrinol, 11, 887, 10.1046/j.1365-2826.1999.00405.x · DOI
- Okuyama-Tamura M, 2003, Neurosci Lett, 342, 206, 10.1016/S0304-3940(03)00261-1 · DOI
- Pariante CM, 2003, J Neuroendocrinol, 15, 811, 10.1046/j.1365-2826.2003.01058.x · DOI · Paper page
- Pariante CM, 2002, N Engl J Med, 347, 148, 10.1056/NEJM200207113470221 · DOI
- Pariante CM, 2002, Biol Psychiatry, 51, 922, 10.1016/S0006-3223(01)01314-2 · DOI
- Pariante CM, 2004, Psychopharmacology (Berl), 177, 200, 10.1007/s00213-004-1925-4 · DOI
- Pariante CM, 1999, Endocrinology, 140, 4359, 10.1210/endo.140.9.6986 · doi:10.1210/endo.140.9.6986 · Paper page
- 10.1677/joe.0.1690309 · DOI
- Pariante CM, 2004, Psychoneuroendocrinology, 29, 423, 10.1016/j.psyneuen.2003.10.009 · DOI · Paper page
- Pariante CM, 2004, Br J Psychiatry, 185, 5, 10.1192/bjp.185.1.5 · DOI · Paper page
- Peiffer A, 1991, Psychoneuroendocrinology, 16, 505, 10.1016/0306-4530(91)90034-Q · DOI
- Pepin MC, 1989, Brain Res Mol Brain Res, 6, 77, 10.1016/0169-328X(89)90031-4 · DOI
- Pepin MC, 1992, Mol Pharmacol, 41, 1016, 10.1016/S0026-895X(25)09226-0 · DOI
- Pridmore S, 1999, Psychiatry Clin Neurosci, 53, 33, 10.1046/j.1440-1819.1999.00603.x · DOI
- Prima V, 2000, J Steroid Biochem Mol Biol, 72, 1, 10.1016/S0960-0760(99)00146-6 · DOI
- 10.1176/appi.ajp.160.9.1554 · DOI · Paper page
- Rangarajan PN, 1992, Mol Endocrinol, 6, 1451
- Rasenick MM, 1996, J Clin Psychiatry, 57, 49
- Reid PD, 1999, Aust N Z J Psychiatry, 33, 274, 10.1046/j.1440-1614.1999.00550.x · DOI
- 10.1016/j.biopsych.2006.02.007 · DOI · Paper page
- Rubin R, 2001, Hormones, brain and behaviour, 467
- Rupprecht R, 1991, J Affect Disord, 22, 31, 10.1016/0165-0327(91)90080-C · DOI
- Sanchez ER, 1994, Mol Endocrinol, 8, 408
- 10.1016/S0960-0760(02)00263-7 · DOI · Paper page
- Schmidt TJ, 1994, Receptor, 4, 229
- Silver PJ, 1986, Eur J Pharmacol, 121, 65, 10.1016/0014-2999(86)90393-6 · DOI
- 10.1016/0006-8993(91)90463-6 · DOI
- Stewart JW, 2005, J Affect Disord, 86, 161, 10.1016/j.jad.2005.01.009 · DOI
- Szabo D, 1999, Cancer Lett, 139, 115, 10.1016/S0304-3835(99)00020-8 · DOI
- Tasker JG, 2006, Endocrinology, 147, 5549, 10.1210/en.2006-0981 · DOI · Paper page
- Varga A, 1996, Anticancer Res, 16, 209
- Vedder H, 1999, J Psychiatr Res, 33, 303, 10.1016/S0022-3956(99)00006-0 · DOI
- Wassef A, 1990, Psychoneuroendocrinology, 15, 59, 10.1016/0306-4530(90)90047-D · DOI
- Weiss J, 2003, J Pharmacol Exp Ther, 305, 197, 10.1124/jpet.102.046532 · DOI · Paper page
- Whalley LJ, 1986, Br Med J (Clin Res Ed), 292, 859, 10.1136/bmj.292.6524.859 · DOI
- Wodarz N, 1991, J Affect Disord, 22, 241, 10.1016/0165-0327(91)90070-9 · DOI
- Wodarz N, 1992, J Affect Disord, 25, 31, 10.1016/0165-0327(92)90090-S · DOI · Paper page
- Yau JL, 2007, Neuropsychopharmacology
- Yehuda R, 2001, J Clin Psychiatry, 64, 41
- Yehuda R, 1993, Biol Psychiatry, 34, 18, 10.1016/0006-3223(93)90252-9 · DOI · Paper page
- Yehuda R, 2004, Biol Psychiatry, 55, 1110, 10.1016/j.biopsych.2004.02.010 · DOI · Paper page
- Yehuda R, 2002, Biol Psychiatry, 52, 393, 10.1016/S0006-3223(02)01357-4 · DOI · Paper page
- Yehuda R, 2006, Neuropsychopharmacology, 31, 189, 10.1038/sj.npp.1300862 · DOI
- Young EA, 1991, Arch Gen Psychiatry, 48, 693, 10.1001/archpsyc.1991.01810320017003 · DOI · Paper page
- Yuuki N, 2005, Acta Psychiatr Scand, 112, 257, 10.1111/j.1600-0447.2005.00625.x · DOI
- Zobel AW, 1999, Am J Psychiatry, 156, 949–951, 10.1176/ajp.156.6.949 · DOI · Paper page
- Zwanzger P, 2003, Psychoneuroendocrinology, 28, 376, 10.1016/S0306-4530(02)00029-X · DOI
Cited by
The glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592
“Alterations in MDR PGP activity may thus lead to varying concentrations of available glucocorticoid hormones in different cells and tissues and thereby contribute to glucocorticoid resistance (Carvalho and Pariante, 2008).”
BackgroundSelf-citationGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
Self-citationThe neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Zunszain, P. A., Hepgul, N., & Pariante, C. M. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_211 · Cited by 303
Self-citationNeuronal plasticity: A link between stress and mood disorders
Calabrese, F., Molteni, R., Racagni, G., & Riva, M. A. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.014 · Cited by 301
Metadata
- Authors
- Carvalho, L. A., & Pariante, C. M.
- Venue
- Stress
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 11
- Issue
- 6
- Pages
- 411-424
- ISSN
- 1025-3890
- 1607-8888
- Cited by
- 56
- References
- 33
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vitro modulation of the glucocorticoid receptor by antidepressants. https://app.cochat.ai/papers/10.1080/10253890701850759
- The paper
- Carvalho, L. A., & Pariante, C. M. (2008). In vitro modulation of the glucocorticoid receptor by antidepressants. Stress. https://doi.org/10.1080/10253890701850759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.